Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups

[1]  Liying Xiao,et al.  1H NMR-based metabonomic and pattern recognition analysis for detection of oral squamous cell carcinoma. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[2]  Stefano Tiziani,et al.  Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. , 2009, Neoplasia.

[3]  J. Garcia-conde,et al.  Cryptochrome-1 expression: a new prognostic marker in B-cell chronic lymphocytic leukemia , 2009, Haematologica.

[4]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[5]  I. Benet,et al.  Analysis of chronic lymphotic leukemia transcriptomic profile: differences between molecular subgroups , 2009, Leukemia & lymphoma.

[6]  W. Strittmatter,et al.  Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia , 2008, Leukemia.

[7]  J. Lindon,et al.  Systems biology: Metabonomics , 2008, Nature.

[8]  J. Garcia-conde,et al.  ZAP-70 mRNA expression provides clinically valuable information in early-stage chronic lymphocytic leukemia , 2008, Haematologica.

[9]  R. Gerszten,et al.  Application of metabolomics to cardiovascular biomarker and pathway discovery. , 2008, Journal of the American College of Cardiology.

[10]  P. Elliott,et al.  High-throughput 1H NMR-based metabolic analysis of human serum and urine for large-scale epidemiological studies: validation study. , 2008, International journal of epidemiology.

[11]  K. Kaski,et al.  1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death , 2008, Molecular systems biology.

[12]  R. Weinshilboum,et al.  Metabolomics: a global biochemical approach to drug response and disease. , 2008, Annual review of pharmacology and toxicology.

[13]  T. Ebbels,et al.  Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts , 2007, Nature Protocols.

[14]  H. Keun,et al.  Application of metabonomics in drug development. , 2007, Pharmacogenomics.

[15]  J. Philippé,et al.  Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia. , 2007, Clinical chemistry.

[16]  K. Stamatopoulos,et al.  ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia , 2007, Leukemia.

[17]  G. Wider,et al.  Concentration measurements by PULCON using X‐filtered or 2D NMR spectra , 2006, Magnetic resonance in chemistry : MRC.

[18]  L. Eriksson.  Multi- and megavariate data analysis , 2006 .

[19]  Alan Hutson,et al.  Detection of epithelial ovarian cancer using 1H‐NMR‐based metabonomics , 2005, International journal of cancer.

[20]  A. Gottschalk.  Umstimmung des Zellstoffwechsels als Grundlage Pathologischer Reaktionen , 2005, Klinische Wochenschrift.

[21]  M. Catherwood,et al.  Routine Analysis of IgVH Mutational Status in CLL Patients using BIOMED-2 Standardized Primers and Protocols , 2004, Leukemia & lymphoma.

[22]  Arthur Weiss,et al.  ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. , 2004, The New England journal of medicine.

[23]  Adrian Wiestner,et al.  ZAP-70 expression and prognosis in chronic lymphocytic leukaemia , 2004, The Lancet.

[24]  W. Dröge,et al.  Plasma glutamate levels, lymphocyte reactivity and death rate in patients with bronchial carcinoma , 2004, Journal of Cancer Research and Clinical Oncology.

[25]  G. Dighiero,et al.  Unsolved issues in CLL biology and management , 2003, Leukemia.

[26]  M Hummel,et al.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936 , 2003, Leukemia.

[27]  I. Wilson,et al.  Understanding 'Global' Systems Biology: Metabonomics and the Continuum of Metabolism , 2003, Nature Reviews Drug Discovery.

[28]  Adrian Wiestner,et al.  ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. , 2003, Blood.

[29]  Emili Montserrat,et al.  ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. , 2003, The New England journal of medicine.

[30]  G. Oremek,et al.  Tumor M2-PK levels in haematological malignancies. , 2003, Anticancer research.

[31]  J. Nicholson,et al.  Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics , 2002, Nature Medicine.

[32]  Axel Benner,et al.  Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. , 2002, Blood.

[33]  D. Oscier,et al.  Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. , 2002, Blood.

[34]  T. Hamblin.  Chronic lymphocytic leukaemia: one disease or two? , 2002, Annals of Hematology.

[35]  P. Vaupel,et al.  Pyruvate kinase type M2: a crossroad in the tumor metabolome , 2002, British Journal of Nutrition.

[36]  David Botstein,et al.  Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia , 2001, The Journal of experimental medicine.

[37]  M. Prokocimer,et al.  Thiamine deficiency in patients with B-chronic lymphocytic leukaemia: a pilot study , 2001, Postgraduate medical journal.

[38]  K. Do,et al.  CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. , 2001, Blood.

[39]  C Stratowa,et al.  CDNA microarray gene expression analysis of B‐cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking , 2001, International journal of cancer.

[40]  P. Musto,et al.  CD38 Expression Correlates with Adverse Biological Features and Predicts Poor Clinical Outcome in B-Cell Chronic Lymphocytic Leukemia , 2001, Leukemia & lymphoma.

[41]  G. Capelli,et al.  Clinical significance of CD 38 expression in chronic lymphocytic leukemia , 2001 .

[42]  H. Grimm,et al.  Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells. , 2000, Anticancer research.

[43]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[44]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[45]  K. Usadel,et al.  The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma. , 1999, Anticancer Research.

[46]  S. Gygi,et al.  Correlation between Protein and mRNA Abundance in Yeast , 1999, Molecular and Cellular Biology.

[47]  K. Maloum,et al.  Chlorambucil in Indolent Chronic Lymphocytic Leukemia , 1998 .

[48]  D F Horrobin,et al.  Essential fatty acids: molecular and cellular basis of their anti-cancer action and clinical implications. , 1998, Critical reviews in oncology/hematology.

[49]  K. Maloum,et al.  Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. , 1998, The New England journal of medicine.

[50]  Serge Akoka,et al.  A new method for absolute quantitation MRS metabolites , 1997, Magnetic resonance in medicine.

[51]  C. Boschek,et al.  The Role of Phosphometabolites in Cell Proliferation, Energy Metabolism, and Tumor Therapy , 1997, Journal of bioenergetics and biomembranes.

[52]  N. Robillard,et al.  Immunophenotypic characterization of acute leukemias and chronic lymphoproliferative disorders: practical recommendations and classifications. , 1996, Hematology and cell therapy.

[53]  Mika Ala-Korpela,et al.  1H NMR spectroscopy of human blood plasma , 1995 .

[54]  R. Bohle,et al.  Nutrition and allorejection impact of lipids. , 1995, Transplant immunology.

[55]  M. Spraul,et al.  750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. , 1995, Analytical chemistry.

[56]  J C Lindon,et al.  Pattern recognition classification of the site of nephrotoxicity based on metabolic data derived from proton nuclear magnetic resonance spectra of urine. , 1994, Molecular pharmacology.

[57]  J. Vion-Dury,et al.  Quantitation of metabolites in human blood serum by proton magnetic resonance spectroscopy. A comparative study of the use of formate and TSP as concentration standards , 1992, NMR in biomedicine.

[58]  Nouna Kettaneh-Wold,et al.  Analysis of mixture data with partial least squares , 1992 .

[59]  D. Catovsky,et al.  Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival , 1989, British journal of haematology.

[60]  Ian D. Wilson,et al.  HIGH RESOLUTION PROTON MAGNETIC RESONANCE SPECTROSCOPY OF BIOLOGICAL FLUIDS , 1989 .

[61]  S. Daefler,et al.  Cholesterol modulation of membrane fluidity and ecto-nucleotide triphosphatase activity in human normal and CLL lymphocytes. , 1987, Anticancer research.

[62]  S. Daefler,et al.  Cell membrane fluidity in chronic lymphocytic leukemia (CLL) lymphocytes and its relation to membrane receptor expression. , 1987, Journal of experimental pathology.

[63]  G. Bodenhausen,et al.  Principles of nuclear magnetic resonance in one and two dimensions , 1987 .

[64]  S. Wold.  Cross-Validatory Estimation of the Number of Components in Factor and Principal Components Models , 1978 .

[65]  J. Binet,et al.  A clinical staging system for chronic lymphocytic leukemia. Prognostic significance , 1977, Cancer.

[66]  D C Case,et al.  Clinical staging of chronic lymphocytic leukemia. , 1977, The Journal of the Maine Medical Association.

[67]  M. Shinitzky,et al.  Cholesterol as a bioregulator in the development and inhibition of leukemia. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[68]  H. W. Chen,et al.  Stimulation of sterol synthesis in peripheral leukocytes of leukemic mice. , 1974, Cancer research.

[69]  H. C. Maneche.  Blood pyruvate in malignant neoplastic disorders. , 1966, Clinical chemistry.

[70]  S. Meiboom,et al.  Modified Spin‐Echo Method for Measuring Nuclear Relaxation Times , 1958 .

[71]  W. Kempner.  THE NATURE OF LEUKEMIC BLOOD CELLS AS DETERMINED BY THEIR METABOLISM. , 1939, The Journal of clinical investigation.